Colorectal clinical trials: What is on the horizon?

Daniel H. Ahn; Richard M. Goldberg

doi:10.2217/fon.15.327

Colorectal clinical trials: What is on the horizon?

Daniel H. Ahn, Richard M. Goldberg

Hematology/Oncology

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.

Original language	English (US)
Pages (from-to)	525-531
Number of pages	7
Journal	Future Oncology
Volume	12
Issue number	4
DOIs	https://doi.org/10.2217/fon.15.327
State	Published - Feb 2016

Keywords

colorectal cancer
immunotherapy
next-generation sequencing
targeted therapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon.15.327

Cite this

@article{791d7b0b995e4b9ebc1e195ae35cc5ef,

title = "Colorectal clinical trials: What is on the horizon?",

abstract = "Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.",

keywords = "colorectal cancer, immunotherapy, next-generation sequencing, targeted therapy",

author = "Ahn, {Daniel H.} and Goldberg, {Richard M.}",

note = "Funding Information: RM Goldberg has research support to The Ohio State University to conduct clinical trials and serves as a paid consultant to Merck for the development of pembrolizumab in gastrointestinal cancers. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2016",

month = feb,

doi = "10.2217/fon.15.327",

language = "English (US)",

volume = "12",

pages = "525--531",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "4",

}

TY - JOUR

T1 - Colorectal clinical trials

T2 - What is on the horizon?

AU - Ahn, Daniel H.

AU - Goldberg, Richard M.

N1 - Funding Information: RM Goldberg has research support to The Ohio State University to conduct clinical trials and serves as a paid consultant to Merck for the development of pembrolizumab in gastrointestinal cancers. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2016 Future Medicine Ltd.

PY - 2016/2

Y1 - 2016/2

N2 - Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.

AB - Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.

KW - colorectal cancer

KW - immunotherapy

KW - next-generation sequencing

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84957618592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957618592&partnerID=8YFLogxK

U2 - 10.2217/fon.15.327

DO - 10.2217/fon.15.327

M3 - Review article

C2 - 26777152

AN - SCOPUS:84957618592

SN - 1479-6694

VL - 12

SP - 525

EP - 531

JO - Future Oncology

JF - Future Oncology

IS - 4

ER -

Colorectal clinical trials: What is on the horizon?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this